Table 3 Pharmacokinetic parameters of patients treated with 100–260 mg m−2 SPI-77 i.v. during days 1–22

From: Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer

 

AUC1–22 (h  μ g ml−1)

Clearance (l h−1)

V d (l)

Half-life (h)

Dose SPI-77 (mg m−2)

Mean

s.d.

Mean

s.d.

Mean

s.d.

Mean

s.d.

100

8233

2369

0.024

0.01

3.21

1.44

99.28

19.44

200

198 22

6186

0.019

0.002

3.00

0.7

120.83

32.31

260

227 29

4013

0.022

0.004

3.2

0.06

103.95

17.04

  1. AUC=area under the curve; i.v.=intravenous; s.d.=standard deviation; Vd=volume of distribution.
Back to article page